APA (7th ed.) Citation

RE, S., C, Z., KJ, T., BC, C., S, C., S, P., . . . E, F. (2025). Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted oncology, 20(6), 979. https://doi.org/10.1007/s11523-025-01182-0

Chicago Style (17th ed.) Citation

RE, Sanborn, et al. "Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study." Targeted Oncology 20, no. 6 (2025): 979. https://doi.org/10.1007/s11523-025-01182-0.

MLA (9th ed.) Citation

RE, Sanborn, et al. "Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study." Targeted Oncology, vol. 20, no. 6, 2025, p. 979, https://doi.org/10.1007/s11523-025-01182-0.